 Brian Freed
Concepts (518)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA-DRB1 Chains | 8 | 2025 | 108 | 1.790 |
Why?
| | T-Lymphocytes | 22 | 2025 | 1935 | 1.470 |
Why?
| | Epitopes | 4 | 2016 | 473 | 1.240 |
Why?
| | HLA Antigens | 9 | 2024 | 235 | 0.930 |
Why?
| | Genetic Predisposition to Disease | 6 | 2016 | 2271 | 0.910 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1098 | 0.880 |
Why?
| | Lymphocyte Activation | 19 | 2006 | 1109 | 0.870 |
Why?
| | Interleukin-2 | 16 | 2005 | 437 | 0.780 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2022 | 79 | 0.750 |
Why?
| | Hydroquinones | 6 | 2003 | 29 | 0.710 |
Why?
| | Kidney Transplantation | 20 | 2019 | 669 | 0.700 |
Why?
| | HLA-B Antigens | 3 | 2024 | 62 | 0.660 |
Why?
| | HLA-DR Antigens | 5 | 2020 | 223 | 0.610 |
Why?
| | Alleles | 8 | 2025 | 843 | 0.590 |
Why?
| | Tars | 3 | 2006 | 4 | 0.570 |
Why?
| | Graft Rejection | 14 | 2019 | 598 | 0.560 |
Why?
| | Acrolein | 2 | 2007 | 23 | 0.520 |
Why?
| | Immunosuppressive Agents | 13 | 2017 | 858 | 0.500 |
Why?
| | Cyclosporins | 11 | 1991 | 76 | 0.490 |
Why?
| | Vimentin | 2 | 2016 | 51 | 0.490 |
Why?
| | Peptides, Cyclic | 2 | 2016 | 256 | 0.440 |
Why?
| | Catechols | 4 | 2003 | 14 | 0.440 |
Why?
| | Peptides | 2 | 2016 | 925 | 0.430 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2022 | 200 | 0.420 |
Why?
| | Transplantation, Haploidentical | 2 | 2024 | 21 | 0.420 |
Why?
| | Tissue Donors | 6 | 2018 | 391 | 0.410 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2022 | 363 | 0.390 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 232 | 0.390 |
Why?
| | Fetal Blood | 6 | 2024 | 318 | 0.380 |
Why?
| | Smoking | 5 | 2011 | 1501 | 0.380 |
Why?
| | Cord Blood Stem Cell Transplantation | 5 | 2016 | 99 | 0.370 |
Why?
| | Immune Tolerance | 4 | 2025 | 356 | 0.370 |
Why?
| | DNA | 7 | 2007 | 1400 | 0.370 |
Why?
| | Smoke | 5 | 2007 | 140 | 0.360 |
Why?
| | B-Lymphocytes | 7 | 2021 | 816 | 0.360 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 836 | 0.340 |
Why?
| | Humans | 91 | 2024 | 129527 | 0.330 |
Why?
| | Ribonucleotide Reductases | 2 | 2000 | 31 | 0.320 |
Why?
| | Graft Survival | 9 | 2017 | 514 | 0.320 |
Why?
| | Arachis | 1 | 2010 | 109 | 0.320 |
Why?
| | Immunoglobulin E | 1 | 2010 | 330 | 0.300 |
Why?
| | Immunoglobulin G | 4 | 2013 | 851 | 0.300 |
Why?
| | Peanut Hypersensitivity | 1 | 2010 | 140 | 0.300 |
Why?
| | Cells, Cultured | 11 | 2019 | 4087 | 0.280 |
Why?
| | Lymphocytes | 3 | 2013 | 377 | 0.280 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 24 | 0.270 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4073 | 0.270 |
Why?
| | Isoantibodies | 3 | 2017 | 57 | 0.270 |
Why?
| | Plants, Toxic | 3 | 2000 | 22 | 0.260 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2016 | 1058 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2006 | 44 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 40 | 0.250 |
Why?
| | Immune System | 2 | 2021 | 174 | 0.240 |
Why?
| | Histocompatibility Testing | 7 | 2019 | 121 | 0.240 |
Why?
| | Flow Cytometry | 5 | 2016 | 1158 | 0.240 |
Why?
| | Tuberculosis | 2 | 2023 | 273 | 0.240 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 577 | 0.240 |
Why?
| | Mycobacterium tuberculosis | 2 | 2023 | 309 | 0.240 |
Why?
| | Enzyme Inhibitors | 2 | 2000 | 825 | 0.240 |
Why?
| | Antibodies | 3 | 2019 | 398 | 0.230 |
Why?
| | Ethylmaleimide | 3 | 1991 | 18 | 0.230 |
Why?
| | Haplotypes | 3 | 2014 | 474 | 0.230 |
Why?
| | Ganciclovir | 4 | 1997 | 52 | 0.220 |
Why?
| | Cell Line | 10 | 2016 | 2774 | 0.220 |
Why?
| | Cytomegalovirus Infections | 5 | 1997 | 190 | 0.210 |
Why?
| | Gene Frequency | 3 | 2019 | 500 | 0.210 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2014 | 3622 | 0.210 |
Why?
| | Islets of Langerhans | 3 | 1994 | 790 | 0.200 |
Why?
| | Glutamic Acid | 1 | 2025 | 235 | 0.200 |
Why?
| | HLA-A Antigens | 1 | 2022 | 53 | 0.200 |
Why?
| | Collagen | 1 | 2025 | 436 | 0.200 |
Why?
| | HLA-C Antigens | 1 | 2022 | 35 | 0.190 |
Why?
| | Interferon-gamma | 3 | 2005 | 773 | 0.190 |
Why?
| | Cigarette Smoking | 1 | 2023 | 91 | 0.190 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1203 | 0.190 |
Why?
| | Protein Binding | 3 | 2016 | 2121 | 0.190 |
Why?
| | Histocompatibility Antigens | 1 | 2022 | 107 | 0.190 |
Why?
| | Cyclosporine | 5 | 1998 | 263 | 0.180 |
Why?
| | Receptors, KIR | 2 | 2022 | 96 | 0.180 |
Why?
| | Enoxaparin | 1 | 2022 | 59 | 0.180 |
Why?
| | In Vitro Techniques | 9 | 2005 | 1091 | 0.180 |
Why?
| | Central Tolerance | 1 | 2021 | 10 | 0.180 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1438 | 0.180 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 39 | 0.180 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 83 | 0.180 |
Why?
| | Transplantation, Homologous | 9 | 2019 | 402 | 0.170 |
Why?
| | Mice | 18 | 2025 | 16973 | 0.170 |
Why?
| | HLA-DRB4 Chains | 1 | 2020 | 6 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 134 | 0.170 |
Why?
| | Brain Ischemia | 1 | 2024 | 321 | 0.170 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2544 | 0.170 |
Why?
| | Evolution, Molecular | 1 | 2024 | 460 | 0.170 |
Why?
| | Receptors, Interleukin-2 | 5 | 2003 | 64 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2020 | 181 | 0.170 |
Why?
| | Nickel | 1 | 2020 | 54 | 0.170 |
Why?
| | Cell Division | 4 | 1997 | 787 | 0.170 |
Why?
| | Trace Elements | 1 | 2020 | 49 | 0.160 |
Why?
| | Transcription Factors | 2 | 2005 | 1642 | 0.160 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2021 | 126 | 0.160 |
Why?
| | Immunotherapy | 2 | 2021 | 596 | 0.160 |
Why?
| | alpha 1-Antitrypsin | 1 | 2020 | 107 | 0.160 |
Why?
| | Cell Cycle Proteins | 1 | 2003 | 583 | 0.160 |
Why?
| | Animals | 26 | 2025 | 35334 | 0.160 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2019 | 17 | 0.160 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 60 | 0.150 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 63 | 0.150 |
Why?
| | Vascular System Injuries | 1 | 2019 | 73 | 0.150 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 627 | 0.150 |
Why?
| | Insulin | 3 | 1994 | 2313 | 0.150 |
Why?
| | Unrelated Donors | 2 | 2024 | 36 | 0.150 |
Why?
| | Tacrolimus | 2 | 2017 | 193 | 0.150 |
Why?
| | Transcription, Genetic | 2 | 2003 | 1416 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2022 | 695 | 0.140 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 21 | 0.140 |
Why?
| | Herpesvirus 4, Human | 1 | 2018 | 157 | 0.140 |
Why?
| | Hydrogen Peroxide | 3 | 1988 | 317 | 0.140 |
Why?
| | Antiviral Agents | 3 | 2020 | 719 | 0.140 |
Why?
| | Cell Transplantation | 1 | 1997 | 37 | 0.140 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 95 | 0.140 |
Why?
| | Donor Selection | 1 | 2018 | 75 | 0.140 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 208 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2020 | 249 | 0.140 |
Why?
| | Proinsulin | 1 | 1997 | 51 | 0.140 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 115 | 0.130 |
Why?
| | Amino Acid Sequence | 4 | 2016 | 2055 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 363 | 0.130 |
Why?
| | Female | 29 | 2024 | 68650 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2018 | 211 | 0.130 |
Why?
| | Benzoquinones | 1 | 1997 | 48 | 0.130 |
Why?
| | Complement System Proteins | 1 | 2019 | 318 | 0.130 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 166 | 0.130 |
Why?
| | Mice, Inbred BALB C | 5 | 2021 | 1248 | 0.130 |
Why?
| | Genetic Variation | 2 | 2015 | 936 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 956 | 0.130 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2016 | 26 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2000 | 954 | 0.130 |
Why?
| | Adult | 19 | 2024 | 35505 | 0.130 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 61 | 0.130 |
Why?
| | Dextrans | 1 | 2016 | 83 | 0.130 |
Why?
| | Collagen Type II | 1 | 2016 | 48 | 0.130 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 193 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2012 | 220 | 0.130 |
Why?
| | Autoantibodies | 4 | 2021 | 1468 | 0.120 |
Why?
| | Retrospective Studies | 10 | 2024 | 14532 | 0.120 |
Why?
| | Genotype | 3 | 2022 | 1827 | 0.120 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 371 | 0.120 |
Why?
| | Stroke | 1 | 2024 | 1071 | 0.120 |
Why?
| | Genetic Therapy | 1 | 1997 | 286 | 0.120 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 428 | 0.120 |
Why?
| | Resting Phase, Cell Cycle | 2 | 2006 | 15 | 0.120 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 546 | 0.120 |
Why?
| | Protein Kinase C | 1 | 1996 | 261 | 0.120 |
Why?
| | Methylprednisolone | 3 | 1991 | 83 | 0.110 |
Why?
| | Clonal Anergy | 1 | 1994 | 52 | 0.110 |
Why?
| | G1 Phase | 2 | 2006 | 69 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 755 | 0.110 |
Why?
| | Tobacco Smoke Pollution | 1 | 1997 | 231 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2019 | 739 | 0.110 |
Why?
| | Autoimmunity | 2 | 2021 | 863 | 0.110 |
Why?
| | Immunoglobulin Isotypes | 1 | 2013 | 34 | 0.110 |
Why?
| | Lymphocyte Culture Test, Mixed | 7 | 1996 | 50 | 0.110 |
Why?
| | Tumor Cells, Cultured | 4 | 2020 | 931 | 0.110 |
Why?
| | Male | 23 | 2024 | 63586 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 426 | 0.110 |
Why?
| | Cell Cycle | 3 | 2006 | 583 | 0.100 |
Why?
| | Models, Biological | 1 | 2020 | 1717 | 0.100 |
Why?
| | Indoles | 1 | 1996 | 387 | 0.100 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 25 | 0.100 |
Why?
| | Middle Aged | 13 | 2024 | 31087 | 0.100 |
Why?
| | Dried Blood Spot Testing | 1 | 2013 | 95 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 1987 | 400 | 0.100 |
Why?
| | Radioimmunoassay | 5 | 1990 | 173 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 804 | 0.100 |
Why?
| | Models, Animal | 2 | 2013 | 375 | 0.100 |
Why?
| | Transduction, Genetic | 1 | 2013 | 124 | 0.100 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 49 | 0.100 |
Why?
| | Pulmonary Fibrosis | 1 | 2016 | 385 | 0.100 |
Why?
| | Islets of Langerhans Transplantation | 1 | 1992 | 63 | 0.100 |
Why?
| | Postoperative Complications | 5 | 2017 | 2475 | 0.100 |
Why?
| | Leukemia L1210 | 1 | 1992 | 7 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 315 | 0.090 |
Why?
| | Chagas Disease | 1 | 2012 | 38 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 336 | 0.090 |
Why?
| | Lung | 4 | 2007 | 3928 | 0.090 |
Why?
| | Beryllium | 2 | 2005 | 152 | 0.090 |
Why?
| | Child, Preschool | 6 | 2014 | 10499 | 0.090 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 35 | 0.090 |
Why?
| | Bronchiolitis Obliterans | 1 | 2012 | 68 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2135 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 744 | 0.090 |
Why?
| | Blood Banks | 1 | 2011 | 40 | 0.090 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2011 | 14 | 0.090 |
Why?
| | Fibroblasts | 2 | 1994 | 943 | 0.090 |
Why?
| | Mice, Knockout | 5 | 2021 | 2887 | 0.090 |
Why?
| | Transplantation Chimera | 1 | 2011 | 54 | 0.090 |
Why?
| | International Cooperation | 1 | 2011 | 177 | 0.090 |
Why?
| | Maleimides | 1 | 1991 | 21 | 0.090 |
Why?
| | Calcium | 2 | 1994 | 1208 | 0.090 |
Why?
| | Receptors, Transferrin | 2 | 2003 | 22 | 0.090 |
Why?
| | Chromatography, High Pressure Liquid | 7 | 2005 | 584 | 0.090 |
Why?
| | Spleen | 1 | 2013 | 508 | 0.090 |
Why?
| | Serine Endopeptidases | 2 | 2022 | 118 | 0.090 |
Why?
| | Skin Tests | 1 | 2010 | 100 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1614 | 0.080 |
Why?
| | Mitogens | 2 | 1988 | 61 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2013 | 471 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1559 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 382 | 0.080 |
Why?
| | Cesarean Section | 1 | 2011 | 183 | 0.080 |
Why?
| | Antibody Formation | 1 | 1991 | 291 | 0.080 |
Why?
| | Siblings | 1 | 2010 | 216 | 0.080 |
Why?
| | Nicotine | 2 | 2023 | 304 | 0.080 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1326 | 0.080 |
Why?
| | Jurkat Cells | 2 | 2000 | 134 | 0.080 |
Why?
| | Survival Rate | 5 | 2017 | 1870 | 0.080 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 21 | 0.080 |
Why?
| | Base Sequence | 3 | 2012 | 2138 | 0.080 |
Why?
| | HLA-DQ Antigens | 2 | 2000 | 179 | 0.080 |
Why?
| | Lung Transplantation | 1 | 2012 | 290 | 0.080 |
Why?
| | Cricetinae | 3 | 1994 | 280 | 0.080 |
Why?
| | Disease Susceptibility | 1 | 2011 | 333 | 0.080 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2016 | 634 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1995 | 130 | 0.080 |
Why?
| | Cell Survival | 3 | 1997 | 1084 | 0.080 |
Why?
| | Adolescent | 7 | 2014 | 20409 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2012 | 253 | 0.070 |
Why?
| | Allografts | 2 | 2019 | 137 | 0.070 |
Why?
| | Phytohemagglutinins | 4 | 1991 | 29 | 0.070 |
Why?
| | Amino Acids | 1 | 2011 | 487 | 0.070 |
Why?
| | Aged | 6 | 2024 | 22063 | 0.070 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 2827 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 677 | 0.070 |
Why?
| | Genetic Linkage | 2 | 2006 | 296 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 855 | 0.070 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 587 | 0.070 |
Why?
| | Cell Differentiation | 4 | 2021 | 1895 | 0.070 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 204 | 0.070 |
Why?
| | Isoantigens | 1 | 1987 | 14 | 0.070 |
Why?
| | Transcription Factor AP-1 | 1 | 2007 | 88 | 0.070 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 86 | 0.070 |
Why?
| | Follow-Up Studies | 5 | 2018 | 4891 | 0.070 |
Why?
| | Cloning, Molecular | 2 | 1998 | 524 | 0.070 |
Why?
| | Kidney Function Tests | 2 | 2017 | 152 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2450 | 0.060 |
Why?
| | Prognosis | 4 | 2017 | 3772 | 0.060 |
Why?
| | Lung Diseases | 2 | 2006 | 741 | 0.060 |
Why?
| | HLA-B15 Antigen | 1 | 2006 | 13 | 0.060 |
Why?
| | Aldehydes | 1 | 2007 | 144 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 90 | 0.060 |
Why?
| | Muromonab-CD3 | 2 | 1997 | 20 | 0.060 |
Why?
| | Sequence Homology | 1 | 2006 | 39 | 0.060 |
Why?
| | Bone Marrow | 2 | 2021 | 272 | 0.060 |
Why?
| | Butylated Hydroxytoluene | 1 | 2006 | 38 | 0.060 |
Why?
| | Cysteine | 1 | 2007 | 195 | 0.060 |
Why?
| | Microspheres | 1 | 2006 | 131 | 0.060 |
Why?
| | HLA-DP Antigens | 1 | 2005 | 32 | 0.060 |
Why?
| | Phenotype | 3 | 2021 | 3058 | 0.060 |
Why?
| | Autoantigens | 2 | 2021 | 420 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2020 | 2367 | 0.060 |
Why?
| | Phospholipases A | 1 | 2006 | 98 | 0.060 |
Why?
| | Arginine | 1 | 2007 | 262 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2024 | 10232 | 0.060 |
Why?
| | Child | 5 | 2014 | 20932 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 97 | 0.060 |
Why?
| | Transfection | 2 | 1998 | 916 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 161 | 0.060 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2005 | 131 | 0.060 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 32 | 0.060 |
Why?
| | Arteriosclerosis | 1 | 2005 | 85 | 0.060 |
Why?
| | Chemokines, CXC | 1 | 2004 | 70 | 0.060 |
Why?
| | Reoperation | 3 | 1998 | 542 | 0.060 |
Why?
| | Acetylcysteine | 1 | 2005 | 145 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2005 | 207 | 0.060 |
Why?
| | Young Adult | 3 | 2024 | 12438 | 0.060 |
Why?
| | Skin Transplantation | 1 | 2025 | 84 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2011 | 3383 | 0.050 |
Why?
| | Structure-Activity Relationship | 3 | 1991 | 548 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 5429 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1500 | 0.050 |
Why?
| | Amino Acid Substitution | 1 | 2025 | 284 | 0.050 |
Why?
| | Agglutination | 2 | 1997 | 5 | 0.050 |
Why?
| | Berylliosis | 1 | 2005 | 185 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2025 | 277 | 0.050 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2003 | 88 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 37 | 0.050 |
Why?
| | Concanavalin A | 3 | 1988 | 75 | 0.050 |
Why?
| | E2F Transcription Factors | 1 | 2003 | 59 | 0.050 |
Why?
| | Risk Factors | 6 | 2017 | 9779 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2003 | 71 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 711 | 0.050 |
Why?
| | Mesocricetus | 2 | 1992 | 38 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 310 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 373 | 0.050 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 376 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 636 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 1992 | 139 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2734 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2005 | 333 | 0.050 |
Why?
| | Biomarkers | 2 | 2019 | 3968 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 342 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2003 | 128 | 0.050 |
Why?
| | Cell Communication | 2 | 2013 | 298 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2005 | 591 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1987 | 170 | 0.050 |
Why?
| | Drug Synergism | 2 | 1996 | 370 | 0.050 |
Why?
| | Neutrophils | 2 | 2005 | 1209 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2022 | 234 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 2 | 2016 | 412 | 0.050 |
Why?
| | Leukemia | 2 | 2012 | 230 | 0.050 |
Why?
| | Antioxidants | 2 | 2006 | 557 | 0.040 |
Why?
| | Apoptosis | 2 | 2020 | 2488 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.040 |
Why?
| | Iron Chelating Agents | 1 | 2000 | 19 | 0.040 |
Why?
| | Kidney | 4 | 2019 | 1382 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 67 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 84 | 0.040 |
Why?
| | Biopsy | 2 | 2019 | 1087 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2001 | 184 | 0.040 |
Why?
| | RNA | 2 | 1997 | 876 | 0.040 |
Why?
| | Cell Separation | 2 | 2011 | 315 | 0.040 |
Why?
| | Virus Internalization | 1 | 2020 | 47 | 0.040 |
Why?
| | Ganglionic Stimulants | 1 | 2000 | 12 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 372 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 435 | 0.040 |
Why?
| | Antigens, CD | 1 | 2003 | 485 | 0.040 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 77 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 106 | 0.040 |
Why?
| | Dimerization | 1 | 2000 | 193 | 0.040 |
Why?
| | Extracellular Traps | 1 | 2020 | 49 | 0.040 |
Why?
| | Antithrombins | 1 | 2020 | 58 | 0.040 |
Why?
| | Inflammation | 3 | 2006 | 2741 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 619 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1461 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 350 | 0.040 |
Why?
| | Blotting, Western | 2 | 2004 | 1199 | 0.040 |
Why?
| | Arthroplasty, Replacement | 1 | 2020 | 37 | 0.040 |
Why?
| | Nephelometry and Turbidimetry | 2 | 2013 | 13 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 302 | 0.040 |
Why?
| | Tyrosine | 1 | 2000 | 222 | 0.040 |
Why?
| | Luminescent Measurements | 2 | 2013 | 76 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 11 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1873 | 0.040 |
Why?
| | Receptors, Cytokine | 1 | 1999 | 34 | 0.040 |
Why?
| | Cytokines | 1 | 2007 | 2018 | 0.040 |
Why?
| | Xenobiotics | 1 | 1999 | 29 | 0.040 |
Why?
| | Receptors, Interferon | 1 | 1999 | 50 | 0.040 |
Why?
| | Steroid 21-Hydroxylase | 1 | 1999 | 30 | 0.040 |
Why?
| | Antibodies, Monoclonal | 3 | 1991 | 1366 | 0.040 |
Why?
| | Addison Disease | 1 | 1999 | 43 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 29 | 0.040 |
Why?
| | Antigens, CD34 | 2 | 2013 | 88 | 0.040 |
Why?
| | Metallothionein | 1 | 1998 | 25 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 147 | 0.040 |
Why?
| | Immunoglobulin M | 2 | 1991 | 276 | 0.040 |
Why?
| | Virus Activation | 1 | 2018 | 88 | 0.040 |
Why?
| | Virus Latency | 1 | 2018 | 84 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 546 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2005 | 2697 | 0.040 |
Why?
| | Pokeweed Mitogens | 2 | 1988 | 7 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 72 | 0.040 |
Why?
| | Depression, Chemical | 1 | 1997 | 22 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 1998 | 110 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2020 | 280 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 1998 | 1037 | 0.030 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 30 | 0.030 |
Why?
| | 3T3 Cells | 1 | 1997 | 159 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 481 | 0.030 |
Why?
| | Insulin, Long-Acting | 1 | 1997 | 62 | 0.030 |
Why?
| | New York | 1 | 1997 | 127 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 385 | 0.030 |
Why?
| | Sulfhydryl Compounds | 2 | 1991 | 187 | 0.030 |
Why?
| | Guanidines | 1 | 1996 | 37 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 89 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 135 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2021 | 5769 | 0.030 |
Why?
| | S Phase | 1 | 1996 | 75 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 50 | 0.030 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 6 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 201 | 0.030 |
Why?
| | Half-Life | 2 | 1996 | 162 | 0.030 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2015 | 20 | 0.030 |
Why?
| | Liver | 3 | 2007 | 1836 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 257 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 2016 | 90 | 0.030 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 74 | 0.030 |
Why?
| | Iron | 1 | 1997 | 283 | 0.030 |
Why?
| | Cross Reactions | 3 | 1990 | 132 | 0.030 |
Why?
| | Antigens, Viral, Tumor | 1 | 1994 | 7 | 0.030 |
Why?
| | Antigens, CD19 | 1 | 2015 | 120 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1994 | 149 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 274 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2016 | 163 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 306 | 0.030 |
Why?
| | Prevalence | 1 | 2001 | 2561 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2001 | 1261 | 0.030 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2007 | 26 | 0.030 |
Why?
| | Mice, Inbred DBA | 2 | 1992 | 191 | 0.030 |
Why?
| | Thioguanine | 1 | 2013 | 18 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1994 | 454 | 0.030 |
Why?
| | Survivors | 1 | 2016 | 461 | 0.030 |
Why?
| | Immunization, Passive | 1 | 1993 | 86 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2024 | 7052 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2013 | 148 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2013 | 83 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 134 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 163 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 218 | 0.020 |
Why?
| | Survival Analysis | 2 | 2012 | 1270 | 0.020 |
Why?
| | Mice, Inbred C57BL | 3 | 2011 | 5468 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2013 | 141 | 0.020 |
Why?
| | Anticoagulants | 1 | 2016 | 637 | 0.020 |
Why?
| | Mercaptopurine | 1 | 1991 | 15 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 157 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3181 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2062 | 0.020 |
Why?
| | Lymphoma | 1 | 2012 | 197 | 0.020 |
Why?
| | Signal Transduction | 2 | 2021 | 4916 | 0.020 |
Why?
| | Blood Donors | 1 | 2011 | 97 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 646 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 337 | 0.020 |
Why?
| | Glucose | 1 | 1994 | 996 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1684 | 0.020 |
Why?
| | Methylmannosides | 1 | 1989 | 1 | 0.020 |
Why?
| | Cytochalasins | 1 | 1989 | 3 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 16 | 0.020 |
Why?
| | Fetus | 1 | 2013 | 780 | 0.020 |
Why?
| | Colchicine | 1 | 1989 | 24 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1842 | 0.020 |
Why?
| | Monocytes | 2 | 1989 | 554 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 827 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 300 | 0.020 |
Why?
| | Blood Glucose | 1 | 1997 | 2071 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 22 | 0.020 |
Why?
| | Oligoclonal Bands | 1 | 2007 | 20 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1991 | 724 | 0.020 |
Why?
| | Lipid Peroxides | 1 | 1987 | 10 | 0.020 |
Why?
| | DNA Replication | 1 | 1989 | 225 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 172 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1950 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2006 | 41 | 0.020 |
Why?
| | Chemokine CCL8 | 1 | 2006 | 3 | 0.020 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 2006 | 78 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3081 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2006 | 117 | 0.020 |
Why?
| | Age Factors | 1 | 2013 | 3150 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2005 | 266 | 0.010 |
Why?
| | Cytosol | 1 | 2006 | 219 | 0.010 |
Why?
| | NADPH Dehydrogenase | 1 | 2005 | 8 | 0.010 |
Why?
| | Infant | 3 | 2007 | 9005 | 0.010 |
Why?
| | NADH Dehydrogenase | 1 | 2005 | 18 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 1987 | 265 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1987 | 261 | 0.010 |
Why?
| | Chemokine CXCL1 | 1 | 2004 | 72 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2005 | 108 | 0.010 |
Why?
| | Translocation, Genetic | 1 | 2005 | 92 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1987 | 298 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1988 | 1029 | 0.010 |
Why?
| | Mice, Inbred AKR | 1 | 1983 | 35 | 0.010 |
Why?
| | Leukemia, Lymphoid | 1 | 1983 | 27 | 0.010 |
Why?
| | Leukemia, Experimental | 1 | 1983 | 27 | 0.010 |
Why?
| | Lymphokines | 1 | 1983 | 127 | 0.010 |
Why?
| | Acute Disease | 1 | 2006 | 975 | 0.010 |
Why?
| | Necrosis | 1 | 1984 | 234 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 806 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1641 | 0.010 |
Why?
| | Rats | 3 | 2004 | 5470 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1422 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 5423 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1991 | 1708 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 324 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2000 | 16 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 141 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 12 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | United States | 1 | 2016 | 13865 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 347 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2393 | 0.010 |
Why?
| | Prospective Studies | 3 | 1996 | 7150 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 262 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 6412 | 0.010 |
Why?
| | Azathioprine | 1 | 1998 | 50 | 0.010 |
Why?
| | Incidence | 2 | 1995 | 2643 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 869 | 0.010 |
Why?
| | Prednisone | 1 | 1998 | 236 | 0.010 |
Why?
| | Risk Assessment | 1 | 2006 | 3255 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 1996 | 53 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1996 | 115 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 1996 | 202 | 0.010 |
Why?
| | Risk | 1 | 1999 | 857 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1996 | 213 | 0.010 |
Why?
| | Dogs | 1 | 1996 | 385 | 0.010 |
Why?
| | Blood Group Incompatibility | 1 | 1995 | 11 | 0.010 |
Why?
| | ABO Blood-Group System | 1 | 1995 | 39 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 1995 | 154 | 0.010 |
Why?
| | Species Specificity | 2 | 1988 | 568 | 0.010 |
Why?
| | Diabetic Nephropathies | 1 | 1998 | 284 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 308 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 100 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 1994 | 402 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1995 | 602 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2101 | 0.010 |
Why?
| | Length of Stay | 1 | 1994 | 1132 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1988 | 44 | 0.000 |
Why?
| | Deferoxamine | 1 | 1988 | 20 | 0.000 |
Why?
| | Malondialdehyde | 1 | 1988 | 29 | 0.000 |
Why?
| | Biotransformation | 1 | 1988 | 67 | 0.000 |
Why?
| | Injections, Subcutaneous | 1 | 1988 | 146 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1988 | 315 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1986 | 25 | 0.000 |
Why?
| | Kidney Medulla | 1 | 1986 | 34 | 0.000 |
Why?
| | Administration, Oral | 1 | 1988 | 783 | 0.000 |
Why?
| | Kidney Diseases | 1 | 1988 | 382 | 0.000 |
Why?
| | Blood Physiological Phenomena | 1 | 1983 | 13 | 0.000 |
Why?
| | Suppressor Factors, Immunologic | 1 | 1983 | 4 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1983 | 53 | 0.000 |
Why?
| | Thymidine | 1 | 1983 | 60 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1983 | 367 | 0.000 |
Why?
|
|
Freed's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|